Plasmalogen Replacement Therapy
Plasmalogens, a subclass of glycerophospholipids containing a vinyl-ether bond, are one of the major components of biological membranes. Changes in plasmalogen content and molecular species have been reported in a variety of pathological conditions ranging from inherited to metabolic and degenerativ...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a6aa1ea3512148efbd25a5207d060c45 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a6aa1ea3512148efbd25a5207d060c45 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a6aa1ea3512148efbd25a5207d060c452021-11-25T18:19:43ZPlasmalogen Replacement Therapy10.3390/membranes111108382077-0375https://doaj.org/article/a6aa1ea3512148efbd25a5207d060c452021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0375/11/11/838https://doaj.org/toc/2077-0375Plasmalogens, a subclass of glycerophospholipids containing a vinyl-ether bond, are one of the major components of biological membranes. Changes in plasmalogen content and molecular species have been reported in a variety of pathological conditions ranging from inherited to metabolic and degenerative diseases. Most of these diseases have no treatment, and attempts to develop a therapy have been focusing primarily on protein/nucleic acid molecular targets. However, recent studies have shifted attention to lipids as the basis of a therapeutic strategy. In these pathological conditions, the use of plasmalogen replacement therapy (PRT) has been shown to be a successful way to restore plasmalogen levels as well as to ameliorate the disease phenotype in different clinical settings. Here, the current state of PRT will be reviewed as well as a discussion of future perspectives in PRT. It is proposed that the use of PRT provides a modern and innovative molecular medicine approach aiming at improving health outcomes in different conditions with clinically unmet needs.José Carlos BozelliRichard M. EpandMDPI AGarticleplasmalogenplasmalogen-related diseasesdegenerative and metabolic disordersmembrane lipid therapyplasmalogen replacement therapyChemical technologyTP1-1185Chemical engineeringTP155-156ENMembranes, Vol 11, Iss 838, p 838 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
plasmalogen plasmalogen-related diseases degenerative and metabolic disorders membrane lipid therapy plasmalogen replacement therapy Chemical technology TP1-1185 Chemical engineering TP155-156 |
| spellingShingle |
plasmalogen plasmalogen-related diseases degenerative and metabolic disorders membrane lipid therapy plasmalogen replacement therapy Chemical technology TP1-1185 Chemical engineering TP155-156 José Carlos Bozelli Richard M. Epand Plasmalogen Replacement Therapy |
| description |
Plasmalogens, a subclass of glycerophospholipids containing a vinyl-ether bond, are one of the major components of biological membranes. Changes in plasmalogen content and molecular species have been reported in a variety of pathological conditions ranging from inherited to metabolic and degenerative diseases. Most of these diseases have no treatment, and attempts to develop a therapy have been focusing primarily on protein/nucleic acid molecular targets. However, recent studies have shifted attention to lipids as the basis of a therapeutic strategy. In these pathological conditions, the use of plasmalogen replacement therapy (PRT) has been shown to be a successful way to restore plasmalogen levels as well as to ameliorate the disease phenotype in different clinical settings. Here, the current state of PRT will be reviewed as well as a discussion of future perspectives in PRT. It is proposed that the use of PRT provides a modern and innovative molecular medicine approach aiming at improving health outcomes in different conditions with clinically unmet needs. |
| format |
article |
| author |
José Carlos Bozelli Richard M. Epand |
| author_facet |
José Carlos Bozelli Richard M. Epand |
| author_sort |
José Carlos Bozelli |
| title |
Plasmalogen Replacement Therapy |
| title_short |
Plasmalogen Replacement Therapy |
| title_full |
Plasmalogen Replacement Therapy |
| title_fullStr |
Plasmalogen Replacement Therapy |
| title_full_unstemmed |
Plasmalogen Replacement Therapy |
| title_sort |
plasmalogen replacement therapy |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/a6aa1ea3512148efbd25a5207d060c45 |
| work_keys_str_mv |
AT josecarlosbozelli plasmalogenreplacementtherapy AT richardmepand plasmalogenreplacementtherapy |
| _version_ |
1718411338132226048 |